TRASYLOL

Dose: 1.66 ug/kg.min
Single Dose: 1.7 (1.66)
Frequency: As recommended.
Route: IV
Instructions: Maintenance, As Required

. It is of Natural origin and belongs to Polypeptide. It belongs to Trypsin inhibitor pharmacological group on the basis of mechanism of action and also classified in Haemorrhage pharmacological group.The Molecular Weight of Aprotinin is 6511.00. Its pKa is strongly basic.

Aprotinin is contraindicated in conditions like Hypersensitivity.

The symptomatic adverse reactions produced by Aprotinin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Hypersensitivity reactions.

Aprotinin is primarily indicated in conditions like Abnormal blood loss prevention, Fat embolism syndrome, Hyperfibrionolytic haemorrhage, Hyperplasminaemia, Liver transplantation, Muscle relaxation (short to intermediate duration), Pancreatic and endotoxic shock, Pancreatitis, Ruptured intracranial aneurysm, Traumatic and haemorrhagic shock.

Aprotinin is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAtracurium (Besylate)DalteparinEnoxaparinHeparin (Na) and Heparin (Cl)Heparin (Na) and Heparin (Cl)Suxamethonium (Cl) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

IV Inj, IV Inf Store at room temperature, Below 25°C or in refrigerator. Do not Freeze.

Aprotinin hypersensitivity should be tested prior to administration. All patients should receive a test dose to assess possible allergic reaction. Those who have had previous therapy with aprotinin should be treated with special caution to avoid a possible anaphylactic reaction. In patients being given a repeat dose of aprotinin, an HÀ-histamine antagonist can be administered before the loading dose. Safe use of aprotinin in children has not been established.